Genentech

The recent Military Basketball Association (MBA) All-Star Game showed what’s possible when sports, service and community come together – and we were honored to be a part of it. With more than 680,000 veterans and one of the nation’s largest active-duty populations, North Carolina is a key location for us to join the MBA and reaffirm our commitment to supporting veteran-centered healthcare. Hear from Bill Caddell, our Director of Issue Advocacy & Alliances, U.S. External Affairs, as he explains how we’re driving impact with the MBA and working to close persistent gaps in healthcare for those who have served.

Today, we broke ground in Holly Springs, North Carolina, the site of our first East Coast manufacturing facility and a major milestone for Genentech.   This 700,000-square-foot, state-of-the-art facility represents more than $700 million in planned investment and will support the future production of metabolic medicines, including next-generation treatments for obesity.   Alongside Genentech and Roche leaders, policymakers, and community partners, we celebrated not just the start of construction but a shared commitment to U.S.-based innovation and North Carolina’s thriving biotech ecosystem.   We’re proud that this project will bring more than 1,900 jobs to the region and help scale the science that matters most to patients.   Pictured (left to right): U.S. Rep. Deborah Ross; Susanne Hundsbæk-Pedersen, Global Head of Pharma Technical Operations and EVP at Roche; North Carolina Governor Josh Stein; Ashley Magargee, CEO of Genentech; Sean Mayefskie, Mayor of Holly Springs; Cheryl Stallings, Wake County Commissioner; Lee Lilley, North Carolina Secretary of Commerce; Fritz Bittenbender, SVP and Head of Public Affairs and Access at Genentech; and Ralf Heckner, Swiss Ambassador. #Genentech #InnovationInAction #NextGenMedicines

Building a more equitable healthcare system starts with trust that is earned at the community level. When local leaders and organizations shape solutions, real and lasting change follows. From expanding access to care and improving health literacy, to opening doors to clinical research, we’re proud to work alongside trusted partners who bring deep community insights and lived experience to our collaborative efforts. Learn more about how putting community first can lead to improved health outcomes for all. http://spr.ly/6046fvItj

For the 19th year in a row, we’re honored to be named one of the Bay Area’s Top Corporate Philanthropists by the San Francisco Business Times. This recognition reflects our deep commitment to the community we call home, and our unwavering efforts to help it thrive. From supporting inclusive research and breaking down barriers to care to opening doors to STEM careers for future innovators, we’re driving lasting impact through bold, community-driven action. Learn more about our impact: http://spr.ly/6041fsuxN

As we enter #SMAAwarenessMonth, Gregory Rippon, our Vice President and Therapeutic Area Head for Neurology, highlights the impact of treatment options bringing hope to the spinal muscular atrophy (SMA) community – a diverse group of individuals with varying experiences and stages of disease severity and progression. Learn more about how we’re supporting this community through research and innovation: https://lnkd.in/gFKp7R99

This #SMAAwarenessMonth, we’re shedding light on the impact of spinal muscular atrophy (SMA) a rare, progressive neuromuscular condition that can affect an individual's ability to walk, eat or breathe. By combining cutting-edge R&D with insights from patient experiences, we’re working to reduce treatment complexity, improve care delivery, and advance non-invasive, disease-modifying therapies that address unmet needs in SMA. Discover more on how we’re driving progress in SMA research and treatment: https://lnkd.in/gkNfrz4S

50 years ago in Nature, Georges Köhler and César Milstein published their groundbreaking invention of hybridoma technology for the generation of monoclonal antibodies. The transformative impact of this work is demonstrated by the ubiquitous use of antibodies as biomedical research reagents. In Nature Reviews Immunology, our scientists Andrew Chan, Paul Carter and Gregory Martyn commemorate the golden jubilee of monoclonal antibodies by exploring the past, present, and future applications of antibody therapeutics. http://spr.ly/6048fcnem

Our CEO, Ashley Magargee, was recognized in Forbes’ 2025 50 Over 50 list! This honor celebrates inspiring women nationwide who are advancing innovation and driving impact across industries. Throughout her two-decade career at Genentech, Ashley has been instrumental in bringing groundbreaking medicines to people with serious conditions. Since becoming CEO, she has continued to nurture a culture that inspires employees to be their best in service of patients while supporting local communities and helping to ensure equitable access to our innovative medicines. We are so proud to have her at the forefront of enhancing patient care here at Genentech. Congratulations, Ashley — and thank you to Forbes for recognizing her impact! http://spr.ly/6048fe1TA #ForbesOver50 #Leadership #Innovation

What does progress in retinal disease care look like up close? Follow along with Hugh Lin, MD MBA , our VP and Head of Ophthalmology, at the American Society of Retina Specialists (ASRS) annual meeting as he shares a quick look at the cutting-edge science driving our work in retinal disease forward. Check out Hugh’s POV from ASRS in the video below! #ASRS2025

Without treatment, people with wet AMD may experience rapid and sudden symptoms of vision impairment, including dark spots at the center of their vision – like the one shown here. Through ongoing research, we’re committed to helping improve outcomes for people with wet AMD and other retinal diseases. At #ASRS2025, we’re sharing new, long-term Phase III results from our refillable eye implant that underscores our efforts to advance care for this disease: http://spr.ly/6044fklZ8